10-Q: Protagenic Therapeutics Reports Q1 2025 Financial Results, Cites Going Concern Uncertainty

Protagenic Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional financing.

Summary

• Protagenic Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is a biopharmaceutical company focused on developing therapeutics for stress-related neuropsychiatric and mood disorders.
• The company incurred a net loss of $1,440,005 for the three months ended March 31, 2025, compared to a net loss of $1,724,294 for the same period in 2024.
• Research and development expenses decreased to $880,372 from $1,460,746 year-over-year.
• General and administrative expenses increased to $567,736 from $277,613 year-over-year.
• As of March 31, 2025, the company had cash of $872,960 and a working capital deficit of $148,803.
• The company states that it does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued.
• The company anticipates needing to obtain debt or equity financing by the third quarter of 2025.
• The company expresses substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.
• A 1-for-14 reverse stock split was effectuated on May 5, 2025.
• The company is in the process of answering regulatory questions in the US and Germany regarding its lead compound, PT00114.
• The Phase I/IIa clinical trial for PT00114 commenced on September 26, 2023.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the net loss, going concern warning, and need for additional financing. The decrease in R&D expenses is a minor positive, but not enough to offset the overall negative outlook.

Positives

• Research and development expenses decreased by $580,374 year-over-year, indicating potential cost management.
• The company is actively engaged in a Phase I/IIa clinical trial for PT00114, demonstrating progress in its drug development pipeline.
• The company is answering regulatory questions in the US and Germany regarding its lead compound, PT00114, which is a step towards potential regulatory approval.

Negatives

• The company reported a net loss of $1,440,005 for Q1 2025.
• The company's cash balance as of March 31, 2025, was $872,960, which is relatively low.
• The company has a working capital deficit of $148,803 as of March 31, 2025.
• The company expresses substantial doubt about its ability to continue as a going concern.
• The company anticipates needing to obtain debt or equity financing by the third quarter of 2025.
• General and administrative expenses increased by $290,123 year-over-year.

Risks

• The company's limited cash resources and working capital deficit raise concerns about its financial stability.
• The going concern warning indicates a significant risk of the company being unable to continue operations without additional funding.
• The need to obtain debt or equity financing by the third quarter of 2025 introduces uncertainty about the company's future capital structure and potential dilution for existing shareholders.
• The company's reliance on the success of its clinical trials and regulatory approvals exposes it to significant development and regulatory risks.
• The increase in general and administrative expenses could indicate inefficiencies or increased costs associated with operating as a public company.

Future Outlook

The company anticipates further losses in the development of its business and will need to obtain debt or equity financing by the third quarter of 2025 to continue operations.

Management Comments

• The company believes that there is substantial doubt in the Companys ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

Industry Context

Many small biopharmaceutical companies face challenges in securing funding and managing cash flow during the drug development process. The company's focus on neuropsychiatric disorders aligns with a growing area of unmet medical need, but also a competitive landscape.

Comparison to Industry Standards

• It is difficult to compare Protagenic Therapeutics to industry standards without knowing the specifics of their clinical trial stage and pipeline.
• Many early-stage biotech companies face similar liquidity challenges, often relying on venture capital or strategic partnerships to fund operations.
• Companies like Athersys and BioTime have faced similar going concern warnings in the past, highlighting the financial risks inherent in the biotech industry.

Related Party Transactions

• The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen.
• During the year ended December 31, 2021, the Company engaged Agenus Inc., a related party, to perform research and development services.

Stakeholder Impact

• Shareholders face potential dilution if the company raises equity financing.
• Employees face uncertainty due to the company's financial instability and going concern warning.
• The company's ability to develop and commercialize its product candidates could impact patients with neuropsychiatric disorders.

Next Steps

• The company needs to secure debt or equity financing by the third quarter of 2025.
• The company needs to continue its Phase I/IIa clinical trial for PT00114.
• The company needs to answer regulatory questions in the US and Germany regarding PT00114.
• The company needs to demonstrate compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2).
• The company needs to file a public disclosure describing any transactions undertaken by the Company to increase its equity and provide and indication of its equity following those transactions.
• The company needs to provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months.

Key Dates

Keywords

Protagenic Therapeutics, financial results, Q1 2025, going concern, PT00114, clinical trial, neuropsychiatric disorders, biopharmaceutical, reverse stock split, financing